CVS Health is considering a possible $66 billion takeover of Aetna, and Amazon appears to be positioning itself for possible development as a PBM.
The Wall Street Journal reported on Thursday that CVS Health is considering a possible $66 billion takeover of Aetna—the nation’s third-largest health insurer. The deal, if realized, could steer millions of Aetna’s members toward CVS retail pharmacies, walk-in Minute Clinics, and services (including home visits for infusion drugs) at a time when pharmacies are facing stiff competition. Neither company confirmed the report.
CVS is known for its 9000 national pharmacies, but an important part of CVS’s business is its pharmacy benefit manager (PBM) subsidiary that negotiates with health insurers to determine which drugs are cost effective and beneficial, and negotiates discounts from drug manufacturers. If the purchase of Aetna goes forward, it could potentially benefit Aetna’s 44.7 million participants because CVS could offer them lower co-pays if patients shop with them. CVS Caremark has access to customers’ pharmaceutical information and medical needs, notes Mohamed Jalloh, a spokesman for the American Pharmacists Association, so it makes sense that the company would want to expand into full healthcare. For example, the insurer could potentially use information from access to CVS Minute Clinics and retail stores to understand whether patients are complying with medication regimens.
Meanwhile, Amazon appears to be positioning itself for possible development as a PBM (or a partner with one). The St. Louis Post Dispatch reported that a review of public records shows that Amazon has acquired wholesale pharmacy licenses in at least 12 states, including Nevada, Arizona, North Dakota, Louisiana, Alabama, New Jersey, Michigan, Connecticut, Idaho, New Hampshire, Oregon, and Tennessee. Another application is pending in Maine. It is unclear whether Amazon is planning to move into prescription drug delivery, but analysts have raised the possibility that the company is exploring the lucrative business.
Amazon’s pursuit of wholesale pharmacy licenses strengthens the belief that it seeks to enter the drug supply chain, but it remains to be seen whether Amazon will buy or partner with an existing PBM or build such capabilities from within. New Jersey attorney and healthcare consultant Nicodemo Fiorentino, who alerted St. Louis Post Dispatch reporters to the wholesale licensing information, noted that Amazon would not be able to ship prescription drugs or devices directly to consumers; it still needs to obtain a pharmacy license.
The potential CVS—Aetna merger may be one of several signs that “the jig is up” for the PBM industry, said Adams Dudley, professor of medicine and health policy at the University of California San Francisco, in USA Today. “The idea of a PBM was that they would negotiate really well and really hard with the drug companies, and that the insurers didn’t have the knowledge or bandwidth to do that.” Dudley elaborated that it’s become apparent PBMs are not actually saving consumers money because the PBMs “keep all the profits themselves.”
Recently, Anthem Health announced that it is separating from Express Scripts, the largest PBM in the country, and teaming up with CVS Health to establish its own PBM, IngenioRX, which is to begin offering services in 2020.
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.